Analyst Ratings February 10, 2026

Bernstein Keeps Outperform on Vertex Ahead of Quarterly Report, Cites Limited Near-Term Stock Reaction

Analyst maintains $572 target; market attention centers on povetacicept data and a string of analyst upgrades

By Marcus Reed VRTX
Bernstein Keeps Outperform on Vertex Ahead of Quarterly Report, Cites Limited Near-Term Stock Reaction
VRTX

Bernstein has reaffirmed its Outperform rating on Vertex Pharmaceuticals and held a $572 price target ahead of the company's upcoming quarterly results, projecting roughly 21% upside from the current share price. The firm trimmed its revenue model modestly for late 2025 but left earnings per share estimates unchanged. Multiple other brokerages have recently adjusted coverage and price targets, with investor focus concentrated on potential Phase 3 data for povetacicept.

Key Points

  • Bernstein maintained an Outperform rating on Vertex with a $572 price target, implying ~21% upside from $470.87.
  • Bernstein lowered its Q4 2025 revenue forecast to $3,148 million, about 1% below consensus, while keeping EPS at $5.20.
  • Several other brokers adjusted coverage or targets recently, reflecting positive analyst sentiment centered on pipeline prospects such as povetacicept.

Overview

Bernstein has maintained an Outperform rating on Vertex Pharmaceuticals with an unchanged $572.00 price target, which it notes implies about a 21% upside from the prevailing share price of $470.87. Analyst price targets across the street span from $330 to $625, reflecting a broad range of views among equity analysts tracking the company.

Earnings context and volatility

Vertex is scheduled to report quarterly results on Thursday. Bernstein said it expects a relatively muted reaction in the stock around the earnings release unless the company pairs the report with Phase 3 data for povetacicept. The stock has shown low market volatility in recent years, carrying a five-year beta of 0.32, consistent with its historically steady behavior within the biotechnology sector.

Model changes and financials

In its latest update, Bernstein slightly adjusted its financial model for Vertex. The firm now forecasts fourth-quarter 2025 revenue of $3,148 million, a projection that is about 1% below consensus estimates. Bernstein left its earnings per share forecast unchanged at $5.20, aligning with market expectations. Vertex reported total revenue of $11.72 billion and has posted revenue growth of 10.33% over the trailing twelve months.

Outlook for fiscal 2026

Looking further ahead, Bernstein’s view for fiscal year 2026 tracks consensus guidance: high-single-digit sales growth coupled with roughly 10% expense growth. The firm had upgraded Vertex in a prior note, and since that change, questions from analysts have largely centered on the trajectory for povetacicept.

Recent analyst activity

Vertex has been the subject of several recent analyst moves. Barclays initiated coverage with an Overweight rating and a $606 price target, citing confidence in the company’s renal franchise. Evercore ISI raised its price target to $530, pointing to potential for povetacicept and shifting market perspectives. RBC Capital upgraded Vertex from Sector Perform to Outperform and increased its target to $546 based on the prospects for povetacicept. Wolfe Research also moved to Outperform with a $548 target, highlighting evolving dynamics in IgAN and positive indications around atacicept and Sionna. BMO Capital reiterated an Outperform rating and kept a $530 target while noting the early launch and tracking of Journavx for acute pain.

What investors are watching

Market attention ahead of earnings is focused on whether Vertex will release Phase 3 data for povetacicept alongside its quarterly numbers. Bernstein’s commentary suggests that absent such data the earnings event may not trigger a large share-price move given the stock’s low volatility. The range of analyst targets indicates differing assumptions about product launches and pipeline progress.


Key takeaways

  • Bernstein retains Outperform and a $572 target, implying about 21% upside from $470.87.
  • Model tweak reduces Q4 2025 revenue to $3,148 million, roughly 1% below consensus; EPS estimate remains $5.20.
  • Multiple firms have upgraded or adjusted coverage, with price targets from $530 to $606 and a target range of $330 to $625 among analysts.

Risks and uncertainties

  • The absence of simultaneous Phase 3 povetacicept data with the quarterly release could lead to a muted share-price response - this affects equity investors in biotech and related healthcare funds.
  • Analyst projections vary widely, indicating uncertainty around pipeline outcomes and market reception for new products - this introduces forecast risk for institutional and retail shareholders.

Risks

  • If Phase 3 povetacicept data is not released alongside earnings, the stock may see only a muted reaction - impacts biotech equity volatility and investor sentiment.
  • Wide dispersion in analyst price targets points to uncertainty about product launches and clinical outcomes - impacts valuation models used by investors.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026